Tetraphase Pharmaceu (TTPH) 3.78 $TTPH Tetraphase

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 7:13 AM

Tetraphase Pharmaceu (TTPH) 3.78 $TTPH

Tetraphase Pharmaceuticals to Present at 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Mon Aug 08, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 9:10 a.m. Eastern Time at Le Parker Meridien Hotel in New York City.
TTPH: 3.78 (-0.02)

Tetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
GlobeNewswire - Thu Aug 04, 3:52PM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the second quarter ended June 30, 2016, and provided an overview of certain corporate achievements and plans.
TTPH: 3.78 (-0.02)

Tetraphase Pharmaceuticals Initiates Phase 1 Clinical Trial for TP-6076, a Second-Generation Antibiotic Candidate Highly Active Against MDR Bacteria
GlobeNewswire - Mon Aug 01, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the initiation of patient dosing in a phase 1 clinical trial for intravenous (IV) TP-6076, a novel antibiotic candidate being developed for the treatment of serious and life-threatening bacterial infections, including those caused by pathogens otherwise resistant to current treatment options.
TTPH: 3.78 (-0.02)

Tetraphase Pharmaceuticals to Present at 2016 JMP Securities Life Sciences Conference
GlobeNewswire - Wed Jun 15, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 1:30 p.m. Eastern Time at The St. Regis New York Hotel in New York City.
TTPH: 3.78 (-0.02)

Tetraphase Pharmaceuticals Announces Presentation of Data at ASM Microbe 2016
GlobeNewswire - Mon May 23, 7:30AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced seventeen data presentations at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place June 16-20 in Boston, MA. Presentations will include information about the company's lead drug candidate, eravacycline, as well as data from its TP-271 program.
TTPH: 3.78 (-0.02)

The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 80.93 (+0.37), TTPH: 3.78 (-0.02), TRVN: 6.77 (-0.01), ADRO: 14.22 (+0.13), ANAC: 99.06 (-0.14)

Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 80.93 (+0.37), TRVN: 6.77 (-0.01), TTPH: 3.78 (-0.02), VRTX: 94.75 (+0.24), ADRO: 14.22 (+0.13), AMGN: 170.13 (+0.07), ANAC: 99.06 (-0.14)

Nordstrom and Wal-Mart fall, Shake Shack and Nvidia jump
AP - Fri May 13, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:
TTPH: 3.78 (-0.02), SHAK: 35.57 (+0.27), WMT: 72.84 (+1.40), JWN: 51.03 (+0.57), CXR.TO: 11.04 (-0.38), NTK: 85.94 (-0.05), CXRX: 8.43 (-0.28), NVDA: 63.15 (+1.81)

Tetraphase Pharmaceuticals Provides Update on Eravacycline Regulatory and Development Status
GlobeNewswire - Thu May 12, 3:05PM CDT
- Additional phase 3 clinical trial in cIAI planned to support NDA filing -
TTPH: 3.78 (-0.02)

Tetraphase Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:30PM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the first quarter ended March 31, 2016.
TTPH: 3.78 (-0.02)

Buying Stocks: Investors Are Considering These on Thursday April 7
ACCESSWIRE - Thu Apr 07, 12:34PM CDT
MIAMI, FL / ACCESSWIRE / April 7, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. CANN, COOL, TTPH, and EKSO have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
TTPH: 3.78 (-0.02), COOL: 3.75 (-0.09), EKSO: 3.89 (+0.04)

Tetraphase Pharmaceuticals to Present Data at 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
GlobeNewswire - Thu Apr 07, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced five data presentations at the 26 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 9-12 in Amsterdam, Netherlands. Presentations will include information about the company's lead drug candidate, eravacycline, as well as data from its preclinical TP-6076 program.
TTPH: 3.78 (-0.02)

Tetraphase Pharmaceuticals to Present at Needham Conference 2016
GlobeNewswire - Wed Apr 06, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 15 Annual Needham & Co. Healthcare Conference on Wednesday, April 13, 2016 at 11:20 a.m. Eastern Time at The Westin Grand Central Hotel in New York City.
TTPH: 3.78 (-0.02)

EQUITY UPDATE: Goldberg Law PC Files Securities Class Action Lawsuit against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Fri Mar 25, 2:14PM CDT
Goldberg Law PC (www.Goldberglawpc.com) announces that it has filed a class action lawsuit against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(Nasdaq: TTPH). Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, (the "Class Period"

, are encouraged to contact the firm in advance of the March 28, 2016, lead plaintiff motion deadline. The new lawsuit has been filed on behalf of options purchasers and sellers.
TTPH: 3.78 (-0.02)

IMPORTANT DEADLINE REMINDER: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
BusinessWire - Fri Mar 25, 9:50AM CDT
Khang & Khang LLP (the "Firm"

announces that a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(Nasdaq: TTPH). Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, inclusive (the "Class Period"

, are encouraged to contact the Firm prior to the March 28, 2016, lead plaintiff motion deadline.
TTPH: 3.78 (-0.02)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Tetraphase Pharmaceuticals, Inc. and Lead Plaintiff Deadline: March 28, 2016
ACCESSWIRE - Fri Mar 25, 9:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 25, 2016 / Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court for the District of Massachusetts on behalf of those who purchased shares of Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(NASDAQ: TTPH), during the period between March 5, 2015 and September 9, 2015 inclusive (the "Class Period"

.
TTPH: 3.78 (-0.02)

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of Tetraphase Pharmaceuticals Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 28, 2016 - TTPH
PR Newswire - Thu Mar 24, 1:47PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
TTPH: 3.78 (-0.02)

EQUITY ALERT UPDATE: Rosen Law Firm Expands Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. on Behalf of Options Purchasers and Sellers
BusinessWire - Wed Mar 23, 6:07PM CDT
Rosen Law Firm, a global investor rights law firm, has filed a class action lawsuit on behalf of all purchasers of the common stock and call options and sellers of put options of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) from March 5, 2015 through September 8, 2015, all dates inclusive (the "Class Period"

. The lawsuit seeks to recover damages for Tetraphase Pharmaceuticals investors under the federal securities laws.
TTPH: 3.78 (-0.02)

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. and Encourages Investors With Losses to Contact the Firm
BusinessWire - Wed Feb 10, 3:05PM CST
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(Nasdaq: TTPH). Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, (the "Class Period"

, are encouraged to contact the firm in advance of the March 28, 2016, lead plaintiff motion deadline.
TTPH: 3.78 (-0.02)

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Tetraphase Pharmaceuticals, Inc. -- TTPH
GlobeNewswire - Wed Feb 10, 10:03AM CST
Rigrodsky & Long, P.A.:
TTPH: 3.78 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Consumer Debt Balloons to $18.56T Amid Economic Jitters

The Debt Tide Keeps Rising Alright, let’s dive calloused knuckles first into what's cooking with U.S. consumer debt these days. Shockwaves through the wallet world this past September—consumer debt surged to a jaw-dropping $18.56 trillion. That's a hefty climb of 2.9% year-over-year, and for anyone keeping score, it wasn't just about mortgages hiking up their pricey...

Gulliver Prep's New STEAM Complex to Transform Miami

Gulliver Prep Leads the Charge in Education Innovation Gulliver Preparatory School just dropped a bombshell in Miami—almost literally, with their shovels hitting the dirt for a new 95,000-square-foot STEAM complex. It's not some lip-service to educational buzzwords either. This project's part of 'The Next 100: The Centennial Campaign for Gulliver,' a mega drive to...

Day Out Snacks Brings Back Sold-Out Peppermint Bark

Spicing Up the Holidays with a Best-Seller Return You've got to love when a brand nails it in the holiday treat department, and Day Out Snacks is playing a winning hand by bringing back their Peppermint Bark protein balls. Here we are again, one year after they flew off the shelves like Santa spotted on Christmas Eve. And let me tell you, this re-release has the potential...

Huntsman Declares Q4 Dividend: $0.0875 Per Share

Huntsman Corporation Delivers Dividend Update So, here's the lowdown from Huntsman Corporation coming at us on a rather sleepy November morning in 2026. They've announced their fourth quarter dividend—a neat $0.0875 per share. Now, this isn’t exactly hitting us like a seismic shockwave, but every little drip counts when you're invested in NYSE:HUN, which is exactly...

Woolery & Co Boosts M&A Expertise with Debbie Wang

A New Power Player Joins Woolery & Co Let me tell you, every now and then a firm makes a move that absolutely oozes strategic brilliance, and this right here is one of those moments. Woolery & Co, a name that's been making waves in strategic advisory circles, has just added Debbie Wang to their lineup. If you're not familiar, she's fresh from Ropes & Gray LLP where she...

Insulin Delivery Devices: A Billion-Dollar Surge

When's the last time you saw a medical device market promising a $10 billion leap in under five years? Yeah, the insulin delivery devices market's got that kind of upside, projected to skyrocket from $16.92 billion in 2026 to a whopping $26.37 billion by 2031. That's a 9.3% annual growth rate. The numbers and the stakes are both staggering. Regional and Segment Leaders...

O-I Glass Faces Class Action: What Investors Must Know

The Unsettling News for O-I Glass Investors Let me dive right into this mess about O-I Glass, Inc. (NYSE:OI). If you're tangled up in their stock, you probably felt that 15.01% nosedive in your portfolio recently. That's no minor blip. On July 28, 2026, as stocks were virtually put through the shredder, O-I Glass announced they had to cut down their financial guidance for...

Lightwave Logic Delays Spur Legal Investigation

Lightwave Logic Faces Legal Hurdles There's trouble brewing for Lightwave Logic, Inc. (NASDAQ: LWLG) after its decision to push back volume production to 2028 stirred the pot. Shares took a nosedive, opening down by about 15% at $3.73, after the company revealed their foundry process and customer qualifications were dragging at a snail's pace. And as you might expect,...

RELEX Solutions: Dominating Supply Chain Assessments

Standing Tall in the Supply Chain Arena Every now and then, a company manages to stand out in a way that makes even the seasoned market watchers take notice. This time, it's RELEX Solutions grabbing the spotlight. They've been recognized as a Leader in four separate IDC MarketScape assessments for 2026. It's no small feat considering the crowded stage of supply chain...

BSR REIT's Q3 2026 Financials: Strategic Progress Made

BSR REIT Hits Strategic Milestones in Q3 Here's a bit of exciting news hitting us from BSR Real Estate Investment Trust. They've dropped their financial results for the third quarter of 2026. Packed with some solid gains, this quarter wasn't just about the numbers—it was about the moves they've been making underneath it all. So, let's break down what they're up to, and...